Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
PEA wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
6 of 6 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mixed evidence
1 of 3 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both PEA and SAMe have evidence — compare verdict strength side-by-side.
600-1200mg
With meals, Split into 2-3 doses
Micronized or ultra-micronized PEA
400-1600mg for mood; 600-1200mg for joints
On empty stomach, Morning and/or midday
Enteric-coated tablets (SAMe tosylate or butanedisulfonate)
2-8 weeks
4-8 weeks
Ongoing
2-6 weeks
4-8 weeks
4-8 weeks
Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis
Nutrients (2024) · Meta analysis · n=742
These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month.
Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials
Nutrients (2023) · Meta analysis · n=774
PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standard mean difference of 1.68 (95% CI 1.05 to 2.31, p = 0.00001).
Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities
Journal of psychopharmacology (Oxford, England) (2025) · Meta analysis · n=2503
Importantly, these treatments were generally well-tolerated, with no significant increase in all-cause dropouts compared to placebo, highlighting their suitability for clinical use in managing agitation in individuals with ASD or ID.
S-Adenosylmethionine for osteoarthritis of the knee or hip
The Cochrane database of systematic reviews (2009) · Meta analysis · n=656
For pain, the analysis indicated a small SMD of -0.17 (95% CI -0.34 to 0.01), corresponding to a difference in pain scores between SAMe and placebo of 0.4 cm on a 10 cm VAS, with no between trial heterogeneity (I(2) = 0).
Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis
Neuropsychopharmacology reports (2025) · Meta analysis · n=1049
A meta-analysis found no significant difference in response rates between the two treatments (risk ratio [RR] = 0.96, 95% CI: 0.78-1.18) or dropout rates (RR = 1.08, 95% CI: 0.62-1.88).
S-Adenosylmethionine (SAMe) for Liver Health: A Systematic Review
Nutrients (2024) · Systematic review · n=15
The most common doses were SAMe 1000 mg or 1200 mg per day with or without another treatment or natural supplement.
Based on multiple meta-analyses showing ~35% pain reduction. Studies primarily used micronized formulations which may have better bioavailability than standard forms. Most benefits observed within 4-6 weeks of treatment.
Meta-analysis of 656 patients showed small effect size (SMD -0.17) corresponding to only 0.4cm improvement on 10cm pain scale. Effect is modest and barely reaches statistical significance threshold.
AI-estimated from published studies. Interpret as directional guidance.
PEA has a higher evidence score (7.5/10 vs 7/10) and wins in 3 of 3 categories.
For reduce inflammation, PEA has a higher relevance score (85 vs 80).
No known interactions between PEA and SAMe have been documented in our database. However, always consult a healthcare provider before combining supplements.